Multiple Sclerosis News Today | Symptoms, Diagnosis, Treatments
6 天之前 · Get the latest multiple sclerosis news, patient views, and caregiver perspectives from one of the largest MS communities online.
MS prognosis and life expectancy - Multiple Sclerosis News Today
2024年2月13日 · Treatment. Perhaps the most important factor that affects the trajectory of MS in the modern day is treatment.Disease-modifying therapies, known as DMTs, are currently approved in the U.S. and ...
Most Tysabri patients see no disease activity after 6 years: Study
3 天之前 · Disease activity over time. While Tysabri has been approved for nearly two decades in the U.S. and Europe, not many studies have looked at its ability to sustain NEDA-3 over several years of ...
MS treatment Fampyra may help people with poor working memory
4 天之前 · To put that idea to the test, the researchers conducted a small clinical trial (NCT04652557) involving 43 healthy young adults. Participants were randomly assigned to receive Fampyra (10 mg twice ...
Top 10 MS stories of 2023 - Multiple Sclerosis News Today
2024年1月2日 · Throughout 2023, Multiple Sclerosis News Today brought consistent coverage to our readers of the latest scientific research, developments in treatment, and clinical trials for multiple sclerosis (MS).
In MS, progression without relapses drives most disability...
2023年10月6日 · The findings challenge the idea that relapses are the main driver of disability worsening in early relapsing forms of MS, and that progression independent of relapses is exclusive to progressive ...
Treatment of progressive MS hits milestones in recent years: Study
2024年2月21日 · The study, “ Clinical trials for progressive multiple sclerosis: progress, new lessons learned, and remaining challenges,” was published in The Lancet Neurology. MS has traditionally been ...
Top 10 MS Stories of 2022 - Multiple Sclerosis News Today
2022年12月30日 · This is a list of the top 10 most-read articles we published this past year, with a brief description of each. We look forward to continuing to serve as a resource for the MS community in 2023.
Stem Cell Transplant Gaining Ground as MS Therapy Option
2022年3月22日 · The first disease-modifying therapy (DMT) Koenig started in 2013, Tecfidera (dimethyl fumarate), an oral capsule developed and marketed by Biogen, made her symptoms worse, she said. Flushing began ...
Trial of Metformin-Clemastine Combo Enrolls First Patient
2022年4月26日 · This Phase 2 clinical trial (NCT05131828), sponsored by the Cambridge University Hospitals NHS Foundation Trust, aims to enroll about 50 adults, ages 25 to 50, with relapsing-remitting MS who ...